Application 220483

Type
ANDA
Sponsor
SAGENT

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001NOREPINEPHRINE BITARTRATE IN 5% DEXTROSENOREPINEPHRINE BITARTRATESOLUTION;INTRAVENOUSEQ 16MG BASE/250ML (EQ 64MCG BASE/ML)NoNo

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A220483-001NOREPINEPHRINE BITARTRATE IN 5% DEXTROSENOREPINEPHRINE BITARTRATEEQ 16MG BASE/250ML (EQ 64MCG BASE/ML)SOLUTION / INTRAVENOUSAP2026-03-26

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A220483-001AP

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
NOREPINEPHRINE BITARTRATENOREPINEPHRINE BITARTRATEHF Acquisition Co LLC, DBA HealthFirstc90d875c-8e6e-284e-e053-2a95a90a334f2026-06-19Warnings, Adverse reactionsName fallback
NOREPINEPHRINE BITARTRATE IN SODIUM CHLORIDENOREPINEPHRINE BITARTRATEWG Critical Care, LLCddbef60d-c20a-4ada-928f-e87074c08a542026-02-17Warnings, Adverse reactionsName fallback
NOREPINEPHRINE BITARTRATENOREPINEPHRINE BITARTRATEBaxter Healthcare Corporation6363e9b4-29df-4553-904d-a563e5adda6e2026-02-06Warnings, Adverse reactionsName fallback
norepinephrine bitartrateNOREPINEPHRINE BITARTRATEAvenacy, LLCdd4b7827-2fe9-4427-a40a-60f275611bf42026-02-01Warnings, Adverse reactionsName fallback
norepinephrine bitartrateNOREPINEPHRINE BITARTRATENovadoz Pharmaceuticals LLC4b054c27-ed64-40e2-8eba-b7f2ec780a822025-12-16Warnings, Adverse reactionsName fallback
NorepinephrineNOREPINEPHRINE BITARTRATELong Grove Pharmaceuticals, LLC759807dd-61a8-4f6f-8bf5-f6ee773c81bc2025-12-04Warnings, Adverse reactionsName fallback
NOREPINEPHRINE BITARTRATENOREPINEPHRINE BITARTRATEAnthea Pharma Private Limited52e22892-4fc3-4f53-9f39-0b5c66da30402025-11-25Warnings, Adverse reactionsName fallback
Norepinephrine BitartrateNOREPINEPHRINE BITARTRATEBreckenridge Pharmaceutical, Inc.109aa5e6-4e42-4131-97b0-f24d3a4cb4e82025-10-06Warnings, Adverse reactionsName fallback
NOREPINEPHRINE BITARTRATENOREPINEPHRINE BITARTRATEBIOCON PHARMA INC.0ea48ab6-e166-df31-b132-70ef982a2d022025-06-17Warnings, Adverse reactionsName fallback
LEVOPHEDNOREPINEPHRINE BITARTRATEHospira, Inc.2c7dd2b0-cc10-4db6-bf56-6eb154ebeb102025-06-12Warnings, Adverse reactionsName fallback
Norepinephrine bitartrateNOREPINEPHRINE BITARTRATECamber Pharmaceuticals, Inc.baba1002-8b62-4a24-a4e1-53e7a59c785a2025-06-12Warnings, Adverse reactionsName fallback
LEVOPHEDNOREPINEPHRINE BITARTRATEHospira, Inc.c4de72a8-2a75-4984-ce90-e4870226dc122025-06-12Warnings, Adverse reactionsName fallback
Norepinephrine BitartrateNOREPINEPHRINE BITARTRATEAmneal Pharmaceuticals LLC256264b1-ddf6-42b7-8a09-194fffea65e22025-04-24Warnings, Adverse reactionsName fallback
Norepinephrine BitartrateNOREPINEPHRINE BITARTRATERising Pharma Holdings, Inc.e6669ed6-9ebc-4b2d-9a8c-5e318fbd18b42024-11-01Warnings, Adverse reactionsName fallback
NOREPINEPHRINE BITARTRATENOREPINEPHRINE BITARTRATECaplin Steriles Limited2ffda6e7-d45d-4af3-a3b1-250a4c95e7362024-09-28Warnings, Adverse reactionsName fallback
Norepinephrine BitartrateNOREPINEPHRINE BITARTRATEMeitheal Pharmaceuticals Inc.53578ac5-b510-4698-a097-f785bfea9fc02024-06-24Warnings, Adverse reactionsName fallback
Norepinephrine bitartrateNOREPINEPHRINE BITARTRATEGland Pharma Limiteddec04acd-8e66-43c7-80b0-468802eba0932024-05-24Warnings, Adverse reactionsName fallback
Norepinephrine BitartrateNOREPINEPHRINE BITARTRATEHikma Pharmaceuticals USA Inc.39cda6c6-3857-4028-80cf-aef135f8c7e62024-01-10Warnings, Adverse reactionsName fallback
Norepinephrine BitartrateNOREPINEPHRINE BITARTRATESagent Pharmaceuticalscc9ecec5-3bd7-4132-9745-7666bac8ceac2023-12-31Warnings, Adverse reactionsName fallback
Norepinephrine BitartrateNOREPINEPHRINE BITARTRATEBE Pharmaceuticals Inc.c42d425a-094e-4390-b4f9-4bb4b0fbc7d02023-12-30Warnings, Adverse reactionsName fallback

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS 5.1 Tissue Ischemia Administration of Norepinephrine Bitartrate Injection to patients who are hypotensive from hypovolemia can result in severe peripheral and visceral vasoconstriction, decreased renal perfusion and reduced urine output, tissue hypoxia, lactic acidosis, and reduced systemic blood flow despite “normal” blood pressure. Address hypovolemia prior to initiating Norepinephrine Bitartrate Injection [see DOSAGE AND ADMINISTRATION (2.1)]. Avoid Norepinephrine Bitartrate Injection in patients with mesenteric or peripheral vascular thrombosis, as this may increase ischemia and extend the area of infarction. Gangrene of the extremities has occurred in patients with occlusive or thrombotic vascular disease or who received prolonged or high dose infusions. Monitor for changes to the skin of the extremities in susceptible patients. Extravasation of Norepinephrine Bitartrate Injection may cause necrosis and sloughing of surrounding tissue. To reduce the risk of extravasation, infuse into a large vein, check the infusion site frequently for free flow, and monitor for signs of extravasation [see DOSAGE AND ADMINISTRATION (2.1)]. Emergency Treatment of Extravasation To prevent sloughing and necrosis in areas in which extravasation has occurred, infiltrate the ischemic area as soon as possible, using a syringe with a fine hypodermic needle with 5 to 10 mg of phentolamine mesylate in 10 to 15 mL of 0.9% Sodium Chloride Injection in adults. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours. 5.2 Hypotension after Abrupt Discontinuation Sudden cessation of the infusion rate may result in marked hypotension. When discontinuing the infusion, gradually reduce the Norepinephrine Bitartrate Injection infusion rate while expanding blood volume with intravenous fluids. 5.3 Cardiac Arrhythmias Norepinephrine Bitartrate Injection elevates intracellular calcium concentrations and may cause arrhythmias, particularly in the setting of hypoxia or hypercarbia. Perform continuous cardiac monitoring of patients with arrhythmias. 5.4 Allergic Reactions Associated with Sulfite Norepinephrine Bitartrate Injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmati...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following adverse reactions are described in greater detail in other sections: Tissue Ischemia [see WARNINGS AND PRECAUTIONS (5.1)] Hypotension [see WARNINGS AND PRECAUTIONS (5.2)] Cardiac Arrhythmias [see WARNINGS AND PRECAUTIONS (5.3)] The most common adverse reactions are hypertension and bradycardia. The following adverse reactions can occur: Nervous system disorders: Anxiety, headache Respiratory disorders: Respiratory difficulty, pulmonary edema